Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS WIF tablet
Drug: BIIL 284 BS tablet D

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02265653

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS Tablet FF
Other: standard breakfast

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02265666

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: BIIL 284 BS

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02265627

Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine, low dose
Drug: Cilobradine, high dose
Drug: Itraconazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02264041

The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ethanolic Solution From HFA134a-MDI - low
Drug: Ethanolic Solution From HFA134a-MDI - medium
Drug: Ethanolic Solution From HFA134a-MDI - high
Drug: Ethanolic Solution From Respimat®

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02264145

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban tablet
Drug: Lefradafiban double chamber sachet
Drug: Pantoprazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264106

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole ER tablet
Drug: Pramipexole IR tablet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264132

Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin
Drug: Paroxetine

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264184

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan low
Drug: Placebo
Drug: Telmisartan high
Drug: Lacidipine high
Drug: Lacidipine low

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 149

Registration Number: NCT02264158

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-DK-AH 269 CL, drinking solution
Drug: [14C]-DK-AH 269 CL, solution for infusion

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264028

AI-Powered Research

Premium Access

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers